Gross Margin: 75.42%
Is the gross margin high or low?
The gross margin of 75.42% is in line with its 5-year average of 70.25%, near the high end of its 5-year range (61.37%–75.42%).
As of Sunday, June 28, 2026. 3.24% above its 12-month average of 73.06%.
GSK Gross Margin
Reported quarterly gross margin; no daily interpolation.
GSK Average Gross Margin Chart
GSK Current vs Average Gross Margin Chart
GSK Gross Margin Metrics
GROSS MARGIN
75.42%
GROSS MARGIN AVG TTM
73.06%
GROSS MARGIN AVG 3Y
72.11%
GROSS MARGIN AVG 5Y
71.14%
GROSS MARGIN AVG 10Y
68.16%
GROSS MARGIN AVG 15Y
68.19%
GROSS MARGIN AVG 20Y
69.95%
CURRENT VS TTM AVG
+3.24%
CURRENT VS 3Y AVG
+4.60%
CURRENT VS 5Y AVG
+6.03%
CURRENT VS 10Y AVG
+10.66%
CURRENT VS 15Y AVG
+10.61%
CURRENT VS 20Y AVG
+7.83%
GSK Competitors' Gross Margin
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GSK plc (GSK) | $105.20B | 75.42% | 73.06% | 72.11% | 71.14% |
| Medtronic plc (MDT)vs › | $103.66B | 65.02% | 65.17% | 65.34% | 65.75% |
| Bristol-Myers Squibb Company (BMY)vs › | $117.46B | 68.75% | 62.23% | 59.55% | 57.82% |
| McKesson Corporation (MCK)vs › | $89.39B | 3.61% | 3.54% | 3.83% | 4.16% |
| HCA Healthcare, Inc. (HCA)vs › | $86.89B | 34.92% | 41.06% | 39.99% | 47.00% |
| Elevance Health Inc. (ELV)vs › | $85.82B | 23.16% | 26.70% | 26.59% | 26.68% |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $124.70B | 86.28% | 85.57% | 86.56% | 87.08% |
| Stryker Corporation (SYK)vs › | $127.39B | 63.67% | 62.91% | 61.66% | 61.70% |
| CVS Health Corp. (CVS)vs › | $133.13B | 13.87% | 13.78% | 14.92% | 15.96% |
| Cigna Corporation (CI)vs › | $74.81B | 9.30% | 9.98% | 11.47% | 12.36% |
Gross Margin Analysis
Gross Margin
75.4%
(Revenue - COGS) / Revenue
Gross Margin Formula & Definition
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Gross Margin FAQ
- What is the gross margin for GSK plc (GSK)?
- The gross margin for GSK stock is 75.42%.
- Is GSK plc's gross margin high or low?
- The gross margin of 75.42% is in line with its 5-year average of 70.25%, near the high end of its 5-year range (61.37%–75.42%).
- What is the TTM average gross margin for GSK plc (GSK)?
- The TTM average gross margin for GSK stock is 73.06%.
- What is the 3Y average gross margin for GSK plc (GSK)?
- The 3Y average gross margin for GSK stock is 72.11%.
- What is the 5Y average gross margin for GSK plc (GSK)?
- The 5Y average gross margin for GSK stock is 71.14%.
- What is the 10Y average gross margin for GSK plc (GSK)?
- The 10Y average gross margin for GSK stock is 68.16%.
- What is the 15Y average gross margin for GSK plc (GSK)?
- The 15Y average gross margin for GSK stock is 68.19%.
- What is the 20Y average gross margin for GSK plc (GSK)?
- The 20Y average gross margin for GSK stock is 69.95%.
GSK Gross Margin History
| DATE | GROSS MARGIN |
|---|---|
| 2026-03-31 | 75.42% |
| 2025-12-31 | 69.17% |
| 2025-09-30 | 73.58% |
| 2025-06-30 | 72.89% |
| 2025-03-31 | 74.23% |
| 2024-12-31 | 68.47% |
| 2024-09-30 | 70.08% |
| 2024-06-30 | 73.08% |
| 2024-03-31 | 73.24% |
| 2023-12-31 | 69.97% |
| 2023-09-30 | 72.11% |
| 2023-06-30 | 73.08% |
| 2023-03-31 | 72.05% |
| 2022-12-31 | 69.66% |
| 2022-09-30 | 69.05% |
| 2022-06-30 | 68.60% |
| 2022-03-31 | 62.21% |
| 2021-12-31 | 61.37% |
| 2021-09-30 | 69.58% |
| 2021-06-30 | 70.74% |
| 2021-03-31 | 66.57% |
| 2020-12-31 | 63.71% |
| 2020-09-30 | 66.63% |
| 2020-06-30 | 67.88% |
| 2020-03-31 | 64.81% |
| 2019-12-31 | 63.50% |
| 2019-09-30 | 65.42% |
| 2019-06-30 | 66.23% |
| 2019-03-31 | 64.33% |
| 2018-12-31 | 64.57% |
| 2018-09-30 | 67.42% |
| 2018-06-30 | 68.40% |
| 2018-03-31 | 66.89% |
| 2017-12-31 | 66.51% |
| 2017-09-30 | 66.19% |
| 2017-06-30 | 64.22% |
| 2017-03-31 | 65.97% |
| 2016-12-31 | 66.94% |
| 2016-09-30 | 66.52% |
| 2016-06-30 | 67.48% |
| 2016-03-31 | 65.76% |
| 2015-12-31 | 59.58% |
| 2015-09-30 | 64.03% |
| 2015-06-30 | 65.95% |
| 2015-03-31 | 62.59% |
| 2014-12-31 | 67.20% |
| 2014-09-30 | 67.61% |
| 2014-06-30 | 69.03% |
| 2014-03-31 | 68.95% |
| 2013-12-31 | 63.42% |
| 2013-09-30 | 67.57% |
| 2013-06-30 | 70.20% |
| 2013-03-31 | 69.46% |
| 2012-12-31 | 70.44% |
| 2012-09-30 | 67.99% |
| 2012-06-30 | 69.05% |
| 2012-03-31 | 72.62% |
| 2011-12-31 | 72.84% |
| 2011-09-30 | 70.68% |
| 2011-06-30 | 74.05% |
| 2011-03-31 | 71.57% |
| 2010-12-31 | 71.14% |
| 2010-09-30 | 72.02% |
| 2010-06-30 | 76.41% |
| 2010-03-31 | 73.47% |
| 2009-12-31 | 73.82% |
| 2009-09-30 | 73.63% |
| 2009-06-30 | 74.92% |
| 2009-03-31 | 73.60% |
| 2008-12-31 | 71.74% |
| 2008-09-30 | 72.97% |
| 2008-06-30 | 74.24% |
| 2008-03-31 | 76.10% |
| 2007-12-31 | 74.44% |
| 2007-09-30 | 77.50% |
| 2007-06-30 | 78.64% |
| 2007-03-31 | 77.93% |
| 2006-12-31 | 75.74% |
| 2006-09-30 | 78.34% |
| 2006-06-30 | 79.19% |
| 2006-03-31 | 80.49% |
| 2005-12-31 | 78.02% |
| 2005-09-30 | 78.36% |
| 2005-06-30 | 77.98% |
| 2005-03-31 | 77.62% |
| 2004-12-31 | 79.95% |
| 2004-09-30 | 77.55% |
| 2004-06-30 | 79.00% |
| 2004-03-31 | 78.68% |
| 2003-12-31 | 15.24% |
| 2003-09-30 | 139.73% |
| 2003-06-30 | 80.20% |
| 2003-03-31 | 78.74% |
| 2002-12-31 | 77.89% |
| 2002-09-30 | 77.51% |
| 2002-06-30 | 79.50% |
Related Metrics
About GSK plc
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Luke Victor Miels